1-2 of 2
Robert K. Stuart
Close
Sort by
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Saurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, Sandeep Jain, Amer Assal, Jan Cerny, Edward A. Copelan, Andrew Daly, Zachariah DeFilipp, Shahinaz M. Gadalla, Robert Peter Gale, Siddhartha Ganguly, Betty K. Hamilton, Gerhard Carl Hildebrandt, Jack W. Hsu, Yoshihiro Inamoto, Abraham S. Kanate, H. Jean Khoury, Hillard M. Lazarus, Mark R. Litzow, Sunita Nathan, Richard F. Olsson, Attaphol Pawarode, Olle Ringden, Jacob M. Rowe, Ayman Saad, Bipin N. Savani, Harry C. Schouten, Sachiko Seo, Nirav N. Shah, Melhem Solh, Robert K. Stuart, Celalettin Ustun, Ann E. Woolfrey, Jean A. Yared, Edwin P. Alyea, Matt E. Kalaycio, Uday Popat, Ronald M. Sobecks, Wael Saber
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2922–2936.
https://doi.org/10.1182/bloodadvances.2018024844
Published: 2018
Includes: Supplemental data